Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to “Hold” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a sell rating to a hold rating in a report published on Thursday morning, BidAskClub reports.

Several other research analysts also recently commented on the stock. TheStreet raised shares of Amphastar Pharmaceuticals from a c rating to a b- rating in a report on Wednesday, August 7th. ValuEngine downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a report on Friday, September 20th. Finally, Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a hold rating to a buy rating and set a $23.00 price target for the company in a report on Wednesday. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $24.64.

NASDAQ:AMPH traded down $0.59 during trading hours on Thursday, hitting $19.93. The stock had a trading volume of 220,525 shares, compared to its average volume of 195,128. The company has a 50 day simple moving average of $20.83 and a two-hundred day simple moving average of $20.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83. Amphastar Pharmaceuticals has a one year low of $17.71 and a one year high of $25.43. The firm has a market capitalization of $969.16 million, a price-to-earnings ratio of 95.05 and a beta of 1.14.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.05. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The firm had revenue of $79.00 million during the quarter, compared to the consensus estimate of $78.90 million. During the same period last year, the firm earned $0.03 EPS. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. Equities research analysts anticipate that Amphastar Pharmaceuticals will post 0.17 earnings per share for the current year.

In other news, SVP Yakob Liawatidewi sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $20.73, for a total transaction of $103,650.00. Following the completion of the sale, the senior vice president now directly owns 47,188 shares of the company’s stock, valued at approximately $978,207.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $20.78, for a total transaction of $207,800.00. Following the sale, the director now directly owns 49,309 shares of the company’s stock, valued at $1,024,641.02. The disclosure for this sale can be found here. Over the last three months, insiders sold 353,979 shares of company stock valued at $7,405,413. Insiders own 30.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. A.R.T. Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $208,000. JPMorgan Chase & Co. lifted its holdings in shares of Amphastar Pharmaceuticals by 15.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after acquiring an additional 1,314 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $684,000. Nordea Investment Management AB lifted its holdings in shares of Amphastar Pharmaceuticals by 1.7% during the 1st quarter. Nordea Investment Management AB now owns 254,071 shares of the company’s stock worth $5,192,000 after acquiring an additional 4,343 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $88,000. 47.32% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Further Reading: 52-Week High/Low

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BidiPass  Market Capitalization Tops $3.96 Million
BidiPass Market Capitalization Tops $3.96 Million
Maverick Chain Market Capitalization Tops $499,360.00
Maverick Chain Market Capitalization Tops $499,360.00
Ellaism Price Tops $0.0007 on Top Exchanges
Ellaism Price Tops $0.0007 on Top Exchanges
Eligma Token Market Cap Reaches $7.05 Million
Eligma Token Market Cap Reaches $7.05 Million
Marriott International Inc  Expected to Announce Earnings of $1.46 Per Share
Marriott International Inc Expected to Announce Earnings of $1.46 Per Share
Short Interest in Primerica, Inc.  Drops By 6.2%
Short Interest in Primerica, Inc. Drops By 6.2%


© 2006-2019 Ticker Report